A Disintegrin And Metalloproteinase
From Proteopedia
(Difference between revisions)
| (9 intermediate revisions not shown.) | |||
| Line 6: | Line 6: | ||
* '''ADAM10''' cleaves ephrin.<br /> | * '''ADAM10''' cleaves ephrin.<br /> | ||
* '''ADAM13''' details are in [[Molecular Playground/ADAM13]].<br /> | * '''ADAM13''' details are in [[Molecular Playground/ADAM13]].<br /> | ||
| - | * '''ADAM17''' (TACE) processes the tumor necrosis factor-α.<br /> | + | * '''ADAM17''' (TACE or TNF-α converting enzyme) processes the tumor necrosis factor-α.<br /> |
* '''ADAM33''' is implicated in asthma.<br /> | * '''ADAM33''' is implicated in asthma.<br /> | ||
| - | * '''ADAMTS''' is ADAM with thrombospondin motifs. <br /> | + | * '''ADAMTS''' is ADAM with thrombospondin motifs<ref>PMID:15554875</ref>. <br /> |
| - | * '''ADAMTS1''' has anti-angionenic activity. <br /> | + | * '''ADAMTS1''' has anti-angionenic activity<ref>PMID:10811842</ref>. <br /> |
* '''ADAMTS4''' and '''ADAMTS5''' are involved in the degradation of aggrecan.<br /> | * '''ADAMTS4''' and '''ADAMTS5''' are involved in the degradation of aggrecan.<br /> | ||
| - | * '''ADAMTS13''' cleaves | + | * '''ADAMTS13''' cleaves [[Von Willebrand Factor]] involved in blood clotting<ref>PMID:18762209</ref>. |
| - | <ref>PMID:18762209</ref> | + | |
== Disease == | == Disease == | ||
| - | ADAM inhibitors are used in anti-cancer therapy. ADAM33 is implicated in asthma. | + | ADAM inhibitors are used in anti-cancer therapy. '''ADAM10''' is a therapeutic target for cancer and inflammation <ref>PMID:19601831</ref>. '''ADAM17''' is a therapeutic target for multiple diseases <ref>PMID:19601834</ref>. '''ADAM33''' is implicated in asthma. '''ADAM33''' is a therapeutic target for asthma <ref>PMID:38396994</ref>. '''ADAMTS4''' is involved in various CNS pathologies<ref>PMID:28084617</ref>. |
== 3D Structures of A Disintegrin And Metalloproteinase == | == 3D Structures of A Disintegrin And Metalloproteinase == | ||
| Line 21: | Line 20: | ||
</StructureSection> | </StructureSection> | ||
| - | == 3D Structures of A Disintegrin And Metalloproteinase == | ||
| - | |||
| - | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| - | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | |||
| - | *ADAM5 | ||
| - | |||
| - | **[[3hy7]], [[3hyg]] – hADAM5 catalytic domain (mutant) - human<br /> | ||
| - | |||
| - | *ADAM8 | ||
| - | |||
| - | **[[4dd8]] – hADAM8 + batimastat<br /> | ||
| - | |||
| - | *ADAM10 | ||
| - | |||
| - | **[[2ao7]] – bADAM10 - bovine<br /> | ||
| - | **[[6be6]] – hADAM10 <br /> | ||
| - | **[[5l0q]] – bADAM10 + antibody<br /> | ||
| - | **[[6bdz]] – hADAM10 + antibody<br /> | ||
| - | |||
| - | *ADAM17 or TACE or TNF-alpha converting enzyme | ||
| - | |||
| - | **[[2m2f]] – hADAM17 membrane-proximal domain - NMR<br /> | ||
| - | **[[1zxc]], [[2a8h]], [[2ddf]], [[1bkc]] – hADAM17 catalytic domain + inhibitor <br /> | ||
| - | **[[2fv5]], [[2fv9]], [[2i47]], [[3b92]], [[3cki]], [[3e8r]], [[3edz]], [[3ewj]], [[3g42]], [[3l0t]], [[3l0v]], [[3le9]], [[3lea]], [[3lgp]], [[3kmc]], [[3kme]], [[3o64]], [[2oi0]] - hADAM17 catalytic domain (mutant)+ inhibitor<br /> | ||
| - | **[[3cki]] - hADAM17 catalytic domain (mutant) + protein inhibitor<br /> | ||
| - | |||
| - | *ADAM22 | ||
| - | |||
| - | **[[3g5c]] - hADAM22 ectodomain<br /> | ||
| - | **[[5y31]], [[5y2z]] – hADAM22 ectodomain + LGI1<br /> | ||
| - | |||
| - | *ADAM33 | ||
| - | |||
| - | **[[1r54]], [[1r55]] – hADAM33 catalytic domain<br /> | ||
| - | |||
| - | *ADAMTS1 | ||
| - | |||
| - | **[[2jih]], [[3q2g]], [[3q2h]] - hADAMTS1 catalytic domain + inhibitor<br /> | ||
| - | **[[2v4b]] - hADAMTS1 catalytic domain | ||
| - | |||
| - | *ADAMTS4 | ||
| - | |||
| - | **[[3b2z]] - hADAMTS4 residues 213-520<br /> | ||
| - | **[[4wk7]], [[4wke]], [[4wki]] - hADAMTS4 residues 213-439 +inhibitor<br /> | ||
| - | **[[2rjp]] - hADAMTS4 residues 213-520 (mutant) + inhibitor | ||
| - | |||
| - | *ADAMTS5 | ||
| - | |||
| - | **[[2rjq]] - hADAMTS5 residues 262-628 + inhibitor<br /> | ||
| - | **[[3b8z]], [[3hy7]], [[3hy9]], [[3hyg]], [[3ljt]] - hADAMTS5 catalytic domain (mutant) + inhibitor | ||
| - | |||
| - | *ADAMTS13 | ||
| - | **[[3ghm]], [[3ghn]], [[3vn4]] - hADAMTS13 exosite-containing fragment (mutant)<br /> | ||
| - | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Current revision
| |||||||||||
References
- ↑ Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005 Feb 15;386(Pt 1):15-27. PMID:15554875 doi:10.1042/BJ20040424
- ↑ Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest. 2000 May;105(10):1345-52. PMID:10811842 doi:10.1172/JCI8635
- ↑ Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008, Aug 15. PMID:18762209 doi:http://dx.doi.org/10.1016/j.mam.2008.08.001
- ↑ Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009;15(20):2288-99. PMID:19601831 doi:10.2174/138161209788682442
- ↑ Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319-35. PMID:19601834 doi:10.2174/138161209788682398
- ↑ Sleziak J, Gawor A, Błażejewska M, Antosz K, Gomułka K. ADAM33's Role in Asthma Pathogenesis: An Overview. Int J Mol Sci. 2024 Feb 15;25(4):2318. PMID:38396994 doi:10.3390/ijms25042318
- ↑ Lemarchant S, Wojciechowski S, Vivien D, Koistinaho J. ADAMTS-4 in central nervous system pathologies. J Neurosci Res. 2017 Sep;95(9):1703-1711. PMID:28084617 doi:10.1002/jnr.24021
